<DOC>
	<DOCNO>NCT01471860</DOCNO>
	<brief_summary>The purpose clinical investigation evaluate efficacy safety CVRx Barostim Neo System treatment patient heart failure .</brief_summary>
	<brief_title>Barostim Neo System Treatment Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Age least 21 year Symptomatic heart failure despite optimal , stable pharmacological therapy least 4 week Significant carotid plaque stenosis Known suspect baroreflex failure autonomic neuropathy Myocardial infarction , unstable angina , syncope , cerebral vascular accident , SCD , receive defibrillation therapy within past 3 month Heart failure secondary reversible condition</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>